KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6-35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial.

Yoonsun Yoon, Hye-Kyung Cho, Ki Hwan Kim, Su Eun Park, Yae-Jean Kim, Jina Lee, Hwang Min Kim, Nam Hee Kim, Dae Sun Jo, Eun Young Cho, Seon Hee Shin, Jong-Hyun Kim, Ji Hwa Ryu, Ho Keun Park, Yoonyeong Lee, Yun-Kyung Kim

Vaccines (Basel) 14(4) 341

PMID42042817
PMCIDPMC13119535
DOI10.3390/vaccines14040341
发表日期2026-04-27
摘要

摘要

Background: Influenza causes substantial morbidity in young children, particularly those aged 6-35 months. In this age group, optimisation of vaccine dose regimens remains important to ensure adequate immunogenicity while maintaining acceptable safety. This study evaluated the immunogenicity and safety of a full 0.5 mL dose of quadrivalent inactivated influenza vaccine (NBP607-QIV) in young children. Methods: This Phase 3, randomised, double-blind, active-controlled, multicentre study was conducted in Korea, Thailand, and Malaysia. Healthy children aged 6-35 months were randomised 2:1 to receive NBP607-QIV (0.5 mL) or control vaccine (0.25 mL). Immunogenicity was assessed using the haemagglutination inhibition assay. Primary endpoints were non-inferiority of NBP607-QIV versus Agrippal for seroconversion rate (SCR) and adjusted post-vaccination geometric mean titre (GMT) ratio against three shared strains. Immunogenicity against the additional B/Yamagata strain was evaluated according to Committee for Medicinal Products for Human Use (CHMP) criteria. Safety was assessed based on adverse events. Results: A total of 676 participants were randomised, and 675 were included in the safety set. Non-inferiority of NBP607-QIV versus control vaccine was demonstrated for SCR for all shared strains and for the adjusted GMT ratio for A/H1N1 and B/Victoria, but not for A/H3N2. Immunogenicity against the B/Yamagata strain met CHMP criteria for SCR and geometric mean ratio (GMR). Immunogenicity was consistent across prespecified subgroups, and the incidence of adverse events was comparable between groups, with no clinically meaningful safety concerns. Conclusions: NBP607-QIV administered at a 0.5 mL dose demonstrated acceptable immunogenicity and a safety profile comparable to that of a licensed trivalent influenza vaccine in children aged 6-35 months, supporting its use in this paediatric population.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。